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Summary
Pulmonary arterial hypertension is an orphan disease and a model for drug developments
over recent years. Expert centers have focused basic science on the pulmonary vasculature
and the right ventricle, followed by a direct transfer of innovative concepts to clinical
research. Successful examples for translational experimentation are the endothelin
receptor antagonists, prostacyclin receptor agonists, and the activators of soluble
guanylate cyclase. On the other hand, there have been failures such as vasoactive
intestinal peptide, statins, and escitalopram. Several new drugs and gene therapy are
under investigation, thus signiﬁcant advances are anticipated.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Pulmonary hypertension is a hemodynamic and patho-
physiological state that can be found in multiple clinical
conditions, and is deﬁned by an increase in invasively
measured mean pulmonary arterial pressure 25mmHg at
rest.1 Untreated chronic pulmonary arterial hypertension
leads to RV failure and death within 3 years of diagnosis.2
Recently, an updated classiﬁcation and recommendations
for contemporary diagnosis and treatment of PH have been
issued as part of the new ERS/ESC guidelines.1 Incidences
of PH are expected as low as 2.5 cases per million for
pulmonary arterial hypertension (PAH), and as high as 60–70%
of the population with systolic and diastolic left ventricular
dysfunction.
This short update will only focus on group 1 pul-
monary hypertension (i.e. PAH), including idiopathic,
heritable, drugs and toxins induced, PAH associated with
speciﬁc disease (connective tissue disease, HIV, portal
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hypertension, congenital heart disease, schistosomiasis,
chronic haemolytic anaemia), and persistent pulmonary
hypertension of the newborn. For this group most of
treatment evidence is available and applicable. We will also
review drugs in development, and drugs currently under
clinical investigation (Table 1).
Pathophysiology
PAH may be classiﬁed as a disorder of pathological
vasoconstriction. Increased vascular tone in PAH has
been ascribed to endothelial cell dysfunction,3 which
is characterized by a reduced expression of pulmonary
vasodilators and increased expression of vasoconstrictors.4
Alternatively, PAH has recently been understood as the
sequelea of a disordered vascular remodeling process in
response to an unknown injury where thrombotic and
inﬂammatory processes, as well as deregulated repair
by a deﬁciency in proteins of the TGF-beta-family are
prominent. It is possible that both pathophysiologic concepts
are correct, and occurring in sequence. The result is
a loss of functional pulmonary vessels. Patients with a
hemodynamic responder status who later in their disease
process develop severe pulmonary hypertension appear
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Table 1
Treatment of pulmonary arterial hypertension
Class of drug Guideline recommendation1
WHO-FC II WHO-FC III WHO-FC IV
Under investigation
Endothelin receptor antagonists Ambrisentan,
Bosentan
Ambrisentan, Bosentan Ambrisentan,
Bosentan
Macitentan
PDE-5 inhibitors Sildenaﬁl,
Tadalaﬁl
Sildenaﬁl, Tadalaﬁl Sildenaﬁl,
Tadalaﬁl
Activators of soluble guanylate cyclase Riociguat
Prostacyclin analogues Epoprostenol, Iloprost,
Treprostinil, Beroprost
Epoprostenol,
Iloprost,
Treprostinil
Prostacyclin receptor agonists Selexipag
Sex hormones Beta estradiol
RAAS Cilazapril, Enalapril, Captopril
Beta-blockers Carvedilol, Bisoprolol, Metoprolol
Rho-kinase Inhibitors KMUP-1
Gene therapy BMPR-II
eNOS
Vascular endothelial growth factor
Calcitonin-gene-related peptide
Adrenomedullin
Prostacyclin synthase
PDE: phosphodiesterase; RAAS: renin–angiotensin–aldosterone system;
KMUP-1: xanthine derivate 7-[2-[4-(2-chlorophenyl)piperazinyl]-ethyl]-1,3-dimethylxanthine; NOS: nitrate oxide synthase.
to be clinical examples matching this pathophysiologic
concept.
Based on the mechanism of vascular loss, and the
successes of organ transplantation restoring right ventricular
function by introducing an allogeneic pulmonary vascular
bed, recent scientiﬁc efforts have been directed at
regrowing the pulmonary vascular bed with autologous
transformed or inducible stem cells.
Targeted treatments – vasodilators
Initially, alpha- and beta-adrenergic blockers were employed
without favorable results.5 A new era in managing
of patients with pulmonary hypertension began in the
late 1970s with prostacyclins that produced signiﬁcant
pulmonary vasodilator activity.6 Higenbottam7 was the ﬁrst
to employ intravenous prostacyclin in patients in 1984.
Later, new drugs targeting endothelial dysfunction such as
endothelin receptor antagonists and phosphodiesterase-5
(PDE-5) inhibitors were developed.
Prostacyclin is a member of the endogenous prostanoids
family and is synthesized from arachidonic acid. This is
a multistep process, which involves prostacyclin synthase
and cyclooxygenase.8 Prostacyclin is released by endothelial
cells in the pulmonary circulation and its effects are
mediated by a speciﬁc cell-surface receptor, which belongs
to the G-protein coupled receptor class. The receptor has
been located on platelets and endothelial cells.9 Upon
binding of prostacyclin the receptor activates protein kinase
A, leading to inhibition of platelet aggregation, relaxation of
smooth muscle and vasodilation of the pulmonary arteries,
which makes prostacyclins and its analogues powerful drugs
in pulmonary hypertension. Synthetic prostacyclin analogues
epoprostenol, iloprost and treprostinil are in clinical use.
These drugs have improved exercise tolerance, Borg Dyspnea
scores, hemodynamics, and survival. This beneﬁt comes at a
cost of some side effects, particularly during epoprostenol
therapy. This speciﬁc agent has the disadvantage of requiring
a permanent intravenous catheter and an infusion pump,
which may lead to serious complications such as thrombosis,
infection and shock.10
Endothelins comprise a family of 21 amino-acid peptides
that play a key role in the regulation of vascular
tone.11 ET-A and ET-B receptors bind the endothelin
peptides, mainly endothelin-1. While the ET-A receptor is
predominantly expressed on pulmonary smooth muscle cells,
the ET-B receptor is located on both pulmonary vascular
endothelial cells and smooth muscle cells.12 Activation
of the ET-A receptor leads to potent vasoconstriction
that persists after endothelin-1 is dissociated from the
receptor, which is mediated via calcium.13,14 Moreover
endothelin-1 has been described as a potent mitogenic
factor for vascular smooth muscle cells.15 Currently,
there are two commercial endothelin receptor antagonists
approved for pulmonary arterial hypertension, bosentan
and ambrisentan, which inhibit both vasoconstriction and
smooth muscle cell proliferation, thereby improving quality
of life and survival.16
Phosphodiesterase-5 inhibitors like sildenaﬁl enhance
the downstream effects of NO mediated vasodilation by
increasing intracellular cGMP.17 NO has profound anti-
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proliferative effects.18 The levels of cGMP are regulated
by phosphodiesterases (PDE). To date, 11 different families
of PDE isoenzymes have been identiﬁed. PDE-5 is the
main pulmonary PDE target because it is highly expressed
in the lungs. At the same time, its expression is low
in the systemic circulation.19 The expression of PDE-5 is
enhanced in pulmonary hypertension, resulting in increased
metabolism of cGMP.20 In addition to sildenaﬁl, tadalaﬁl is
approved by the FDA.21,22
The ﬁrst oral selective prostacyclin-receptor Agonist
Selexipag was safe and efﬁcacious in a 17-week proof-of-
concept trial with a PVR reduction of 30%. Another recent
development is the class of activators of soluble guanylate
cyclase (Prototype Riociguat) that has been tested and found
efﬁcacious in another proof-of-concept trial.
Targeted treatments – introducing reverse
remodeling
Tyrosine kinase inhibitors (Prototype Imatinib)
Imatinib, a PDGF receptor blocker did not improve 6MWD
in a ﬁrst proof-of-concept trial but reduced PVR by
300 dyn·sec·cm–5, and increased cardiac output, particularly
in patients with severe hemodynamic compromise. Further
compounds in clinical trials are multikinase inhibitors, e.g.
sunitinib.
Targets of new preclinical developments
Beta estradiol
Beta-estradiol has been a substance of interest because
of the protective effect of female gender in pulmonary
vascular disease.23 Its protective effects are mediated
by a reduction of endothelin-1 expression, enhancing
NO- and prostacyclin-synthesis and downregulation of
various adhesion molecules.24 Furthermore, estrogen has
antiproliferative properties.25 Recently, Xu et al. have
shown that beta-estradiol treatment of rats with pulmonary
hypertension led to a reduced degradation of p27(kip1)
by reduction of Skp-2 expression. p27(kip1) is a negative
regulator of pulmonary artery smooth muscle cell growth26
thus reversing vascular remodeling. However, 17beta-
estradiol may induce pulmonary hypertension by inducing
proliferation, which is dependent on an interaction with
serotonin and the 5HT1b receptor.27 Clearly, the role of beta-
estradiol in pulmonary hypertension merits further studies.
Renin–angiotensin–aldosterone system (RAAS)
Angiotensin-converting enzyme 2 (ACE-2) is a homologue
of ACE and represents the counter regulatory axis of
ACE, reducing the vasoconstrictive proliferative, ﬁbrotic
and inﬂammatory effects of angiotensin-2.28 ACE-2 has
mechanistically been implicated in several pulmonary
diseases including acute respiratory distress syndrome,
where a knock-out of ACE-2 led to more severe disease.29
There is a wealth of animal data suggesting that the use
of an ACE-inhibitor or a AT1 receptor antagonist attenuates
development of pulmonary hypertension. Data from human
pilot studies are controversial. While cilazapril reduced
mean pulmonary pressure in patients with congestive heart
failure and captopril reduced pulmonary pressure in patients
with high-altitude pulmonary hypertension, enalapril had no
effect.30 The observation that RAS exerts an effect on the
pulmonary vasculature makes the endogenous counterpart
of ACE – ACE-2 – an interesting target for future drug
development.
RhoA/Rho-kinase
Rho A and its downstream effector Rho-kinase play an
important role in the development of cardiovascular
diseases including pulmonary hypertension. Rho-kinase
mediates a calcium-sensitization in vascular smooth muscle
cells, thereby elevating vascular tone and its inhibitor
has been shown to act as a vasodilator in pre-constricted
arteries.31 Recently, a xanthine derivate called KMUP-1 has
been shown to increase NO synthesis and inhibit RhoA/Rho-
kinase in a rat model of pulmonary hypertension.32 KMUP-1,
a xanthine-based cyclic GMP-enhancing Rho-kinase inhibitor
increased the expression of eNOS, soluble guanylate
cyclase and cGMP, while decreasing PDE-5 and Rho-kinase
expression, leading to calcium desensitization in pulmonary
vascular smooth muscle cells.
Gene therapy
Bull et al. found 106 genes differentially expressed in
PAH lungs, including bone morphogenic protein receptor
II (BMPR-II), vasoactive intestinal peptide and several
chemokine receptors.33 This observation gave rise to the
idea to correct altered gene expression via gene transfer,
carrying the theoretical advantage that there are no
systemic side effects of vasodilatation.34 Several genes have
been targets of gene therapy in preclinical studies including
eNOS,35 vascular endothelial growth factor,36 calcitonin-
gene-related peptide,37 adrenomedullin,38 prostacyclin syn-
thase39 and BMPR-II.40 All of these improved pulmonary
hemodynamics in animal models. At this stage of gene
therapy, benchwork and clinical work run in parallel, with
the expectation of signiﬁcant advances still to come.
Conclusions and clinical implications
Both basic and clinical research have been contributing
to innovative drug developments for PAH, thus improving
quality of life, survival and freedom of hospitalizations in
this orphan disease population.41 Nevertheless, prognosis
of PAH is still dismal, and as clinical studies become
more demanding in an ageing and more comorbid European
population, visionary individuals who are networking in
an environment of decreasing resources drive scientiﬁc
advances.
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